Abstract
Parathyroid hormone (PTH) classically causes bone resorption and bone loss. However, since 1929 (1), it has been known that PTH can also have an anabolic effect on the skeleton. This salutary effect of PTH is the basis for the idea that PTH has the potential to become a therapy for osteoporosis. This chapter will review the effects of endogenous PTH, including lessons learned from primary hyperparathyroidism and the rationale for PTH therapy in osteoporosis. Clinical trials of PTH in osteoporosis, both alone and in combination with other drugs, will also be reviewed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
